Episode 3. Michael Jordan welcomes Adi Zoref-Lorenz to discuss the evolving landscape for secondary HLH and MAS. They explore first-line therapies like anakinra and corticosteroids, the critical importance of identifying underlying triggers, and the value of multidisciplinary care. The episode also covers EBV–HLH, emerging therapies, and practical strategies to monitor complex cases.

Episode 2. Francesca Minoia, a key contributor to the 2016 MAS classification criteria, chats with Michael Jordan to reflect on the study’s impact, the significance of lab trends, and the evolving role of biomarkers in diagnosis. They discuss challenges in early recognition, particularly in patients receiving biologics or presenting with MAS as an initial symptom, and how diagnostic tools are reshaping clinical practice.

Episode 1. “It may not make as much sense to say that someone has HLH as it might to say that they are in HLH.” Scott Canna joins Michael Jordan to explore secondary HLH/MAS from a rheumatology perspective – from clinical definitions to treatment strategies – and why reframing HLH as a state rather than a diagnosis could change clinical thinking. The episode also delves into the role of Epstein–Barr virus (EBV) in triggering HLH and how to manage it effectively.